Related Experiment Video
Updated: Feb 4, 2026

Longitudinal Follow-Up of Urinary Tract Infections and Their Treatment in Mice using Bioluminescence Imaging
Published on: June 14, 2021
Long-term follow-up in PMM2-CDG: are we ready to start treatment trials?
Peter Witters1,2, Tomas Honzik3, Eric Bauchart4
1Pediatrics and Metabolic Center, University Hospitals Leuven, Leuven, Belgium. peter.witters@uzleuven.be.
Purpose:
PMM2-CDG is the most common congenital disorder of glycosylation (CDG), which presents with either a neurologic or multisystem phenotype. Little is known about the longitudinal evolution.
Methods:
We performed data analysis on PMM2-CDG patients' clinical features according to the Nijmegen CDG severity score and laboratory data. Seventy-five patients (28 males) were followed up from 11.0 ± 6.91 years for an average of 7.4 ± 4.5 years.
Results:
On a group level, there was no significant evolution in overall clinical severity. There was some improvement in mobility and communication, liver and endocrine function, and strabismus and eye movements. Educational achievement and thyroid function worsened in some patients. Overall, the current clinical function, the system-specific involvement, and the current clinical assessment remained unchanged. On follow-up there was improvement of biochemical variables with (near) normalization of activated partial thromboplastin time (aPTT), factor XI, protein C, antithrombin, thyroid stimulating hormone, and liver transaminases.
Conclusion:
PMM2-CDG patients show a spontaneous biochemical improvement and stable clinical course based on the Nijmegen CDG severity score. This information is crucial for the definition of endpoints in clinical trials.
Insights
PMM2-CDG patients experience stable clinical symptoms despite biochemical improvements over time. This longitudinal data is vital for future clinical trial endpoint definitions in this common congenital disorder of glycosylation.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Background:
- PMM2-CDG is the most prevalent congenital disorder of glycosylation (CDG).
- CDGs manifest with neurological or multisystemic symptoms.
- Longitudinal data on PMM2-CDG natural history is limited.
Purpose of the Study:
- To investigate the longitudinal evolution of clinical and biochemical features in PMM2-CDG patients.
- To assess changes in disease severity over time using the Nijmegen CDG severity score.
Main Methods:
- Retrospective analysis of clinical and laboratory data from 75 PMM2-CDG patients.
- Average follow-up duration of 7.4 years.
- Assessment of clinical severity, functional status, and biochemical markers.
Main Results:
- No significant change in overall clinical severity was observed on a group level.
- Improvements noted in mobility, communication, liver and endocrine function, and eye movements.
- Biochemical markers, including aPTT, factor XI, protein C, antithrombin, TSH, and liver transaminases, showed improvement or normalization.
Conclusions:
- PMM2-CDG patients exhibit a stable clinical course with spontaneous biochemical improvements.
- The findings provide critical insights for defining clinical trial endpoints in PMM2-CDG research.
Related Concept Videos
Ready Mixed Concrete
Clinical Trials: Overview
Trial and Error and Algorithm
Clinical Trials
There are four phases in a clinical trial. A phase one...
Long-term Depression
Long-term Depression
Calcium Ion Concentration Mechanism
If over...

